

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10536502	
	Filing Date		2005-12-14	
	First Named Inventor	Chris D. Geddes		
	Art Unit	2858		
	Examiner Name			
	Attorney Docket Number	014835-101.02-029		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10536502
Filing Date	2005-12-14
First Named Inventor	Chris D. Geddes
Art Unit	2858
Examiner Name	
Attorney Docket Number	014835-101.02-029

1	FRIEDLANDER, A. M.; Anthrax: Clinical Features, Pathogenesis, and Potential Biological Warfare Threat; Current Clinical Topics in Infectious Diseases; 2000; pp. 335-349; (eds. Reminton, J S. & Schwartz, M. N.) Blackwell Science, Inc., Malden, MA.	<input type="checkbox"/>
2	KUMMERLEN, J. et al.; Enhanced dye fluorescence over silver island films: analysis of the distance dependence; Molecular Physics; 1993; pp. 1031-1046; Vol. 80, No. 5.	<input type="checkbox"/>
3	XU, c. and WEBB, W. W.; Multiphoton Excitation of Molecular Fluorophores and Nonlinear Laser Microscopy; Topics in Fluorescence Spectroscopy: Nonlinear and Two-Photon-Induced Fluorescence; 1997; pp. 471-540; Vol. 5; Plenum Press, New York (ed. J. Lakowicz).	<input type="checkbox"/>
4	WEITZ, D. A. et al.; Fluorescent lifetimes of molecules on silver-island films; Optics Letters; Feb. 1982; pp. 89-91; Vol. 7, No. 2.	<input type="checkbox"/>
5	GLASS, A. M. et al.; Interaction of metal particles with adsorbed dye molecules: absorption and luminescence; Optics Letters; Sept. 1980; pp. 368-370; Vol. 5, No. 9.	<input type="checkbox"/>
6	KREIBIG, U. and GENZEL, L.; Optical Absorption of Small Metallic Particles; Surface Science; 1985; pp. 678-700; Vol. 156; North-Holland, Amsterdam.	<input type="checkbox"/>
7	PASTORIZA-SANTOS, i. and LIZ-MARZAN, L. M.; Reduction of silver nanoparticles in DMF. Formation of monolayers and stable colloids.; Pure Appl. Chem.; 2000; pp. 83-90; Vol. 72, Nos. 1-2.	<input type="checkbox"/>
8	TURNBULL, P. C. B. et al.; Bacillus anthracis but not always anthrax; Journal of Applied Bacteriology; 1992; pp. 21-28; Vol. 72.	<input type="checkbox"/>
9	FARMER, S. C. and PATTEN, T. E.; Synthesis of Luminescent Organic/Inorganic Polymer Nanocomposites; Polym. Mater. Sci. Eng.; 2000; pp. 237-238; Vol. 82.	<input type="checkbox"/>
10	YANG, C.-C. et al.; Deposition of Ultrathin Films by a Withdrawal Method; Thin Solid Films; 1980; pp. 117-127; Vol. 74; printed in the Netherlands.	<input type="checkbox"/>
11	GRABAR, K. C. et al.; Preparation and Characterization of Au Colloid Monolayers; Anal. Chem.; 1995; pp. 735-743; Vol. 67.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10536502
Filing Date	2005-12-14
First Named Inventor	Chris D. Geddes
Art Unit	2858
Examiner Name	
Attorney Docket Number	014835-101.02-029

12	MULLIS, K. B.; Target amplification for DNA analysis by the polymerase chain reaction; Ann. Biol. Clin.; 1990; pp. 579-582; Vol. 48.	<input type="checkbox"/>
13	HAYAKAWA, T. et al.; Field enhancement effect of small Ag particles on the fluorescence from Eu3+-doped SiO2 glass; Applied Physics Letters; March 1999; pp. 1513-1515; Vol. 74, No. 11.	<input type="checkbox"/>
14	WELKOS, S. L. et al.; Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis; Gene; 1988; pp. 287-300; Vol. 69.	<input type="checkbox"/>
15	LAKOWICZ, J. R. and GRZYCZYNSKI, I.; Multiphoton Excitation of Biochemical Fluorophores; Topics in Fluorescence Spectroscopy: Nonlinear and Two-Photon-Induced Fluorescence 1997; pp. 87-144; Vol. 5; ed. J. Lakowicz, Plenum Press, New York.	<input type="checkbox"/>
16	HOLLAND, W. R. and HALL, D. G.; Waveguide mode enhancement of molecular fluorescence; Optics Letters; 1985, pp. 414-416; Vol. 10, No. 8.	<input type="checkbox"/>
17	BARNES, W. L.; Topical review: Fluorescence near interfaces: the role of photonic mode density; Journal of Modern Optics; 1998; pp. 661-669; Vol. 45, No. 4.	<input type="checkbox"/>
18	PETTINGER, B. and GEROLYMATOU, A.; Dyes Adsorbed at Ag-Colloids: Substitution of Fluorescence by Similarly Efficient Surface Fluorescence and Surface Raman Scattering; Ber. Bunsenges. Phys. Chem.; 1984; pp. 359-363; Vol. 88; Verlag Chemie GmbH, D-6940 Weinheim.	<input type="checkbox"/>
19	LOBMAIER, CH. et al.; Direct monitoring of molecular recognition processes using fluorescence enhancement at colloid-coated microplates; Journal of Molecular Recognition; 2001; pp. 215-222; Vol. 14; John Wiley & Sons, Ltd.	<input checked="" type="checkbox"/>
20	GERSTEN, J. L. and NITZAN, A.; Photophysics and Photochemistry Near Surfaces and Small Particles; Surface Science; 1985; pp. 165-189; Vol. 158; North-Holland, Amsterdam.	<input type="checkbox"/>
21	DREXHAGE, K. H.; Interaction of Light with Monomolecular Dye Layers; Progress in Optics, (Wolfe, E., Ed.); 1974; pp. 163-232; North Holland Publishing Company, Amsterdam.	<input type="checkbox"/>
22	PASTEUR, L. et al.; Compte rendu sommaire des experiences faites a Pouilly-le-Fort, pres Melun, sur la vaccination charbonneuse; Comptes Rendus des seances De L'Academie des Sciences; 1881; pp. 1378-83; Vol. 92.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10536502
Filing Date		2005-12-14
First Named Inventor	Chris D. Geddes	
Art Unit		2858
Examiner Name		
Attorney Docket Number		014835-101.02-029

23	STOPA, P. J.; The Flow Cytometry of Bacillus anthracis Spores Revisited; Cytometry; 2000; pp. 237-244; Vol. 41; published by Wiley-Liss, Inc.	<input type="checkbox"/>
24	KREIBIG, U. et al.; Mie Resonances: Sensors for Physical and Chemical Cluster Interface Properties; Ber. Bunsenges. Phys. Chem.; 1997; pp. 1593-1604; Vol. 101, No. 11; Wiley-VCH Verlag GmbH, D-69451 Weinheim.	<input type="checkbox"/>
25	JEANMAIRE, D. L. and VAN DUYNE, R. P.; Surface Raman Spectroelectrochemistry, Part 1. Heterocyclic, Aromatic, and Aliphatic Amines Adsorbed on the Anodized Silver Electrode; J. Electroanal. Chem.; 1977; pp. 1-20; Vol. 84; Printed in the Netherlands.	<input type="checkbox"/>
26	SABANAYAGAM, C. R. et al.; Oligonucleotide immobilization on micropatterned streptavidin surfaces; Nucleic Acids Research; 2000; pg. e33; Vol. 28, No. 8.	<input type="checkbox"/>
27	SHANGKUAN, Y.-H. et al.; Molecular characterization of Bacillus anthracis using multiplex PCR, ERIC-PCR and RAPD; Letters in Applied Microbiology; 2001; pp. 139-145; Vol. 32.	<input type="checkbox"/>
28	LEE, M. A. et al.; Fluorescent detection techniques for real-time multiplex strand specific detection of Bacillus anthracis using rapid PCR; Journal of Applied Microbiology; 1999; pp. 218-223; Vol. 87.	<input type="checkbox"/>
29	BERDAL, B. P. et al.; Field Detection of Francisella tularensis; Scand. J. Infect. Dis.; 2000; pp. 287-291; Vol. 32.	<input type="checkbox"/>
30	LEROY, E. M. et al.; Diagnosis of Ebola Haemorrhagic Fever by RT-PCR in an Epidemic Setting; Journal of Medical Virology; 2000; pp. 463-467; Vol. 60.	<input type="checkbox"/>
31	MAKINO, S.-I. et al.; Detection of anthrax spores from the air by real-time PCR; Letters in Applied Microbiology; 2001; pp. 237-240; Vol. 33.	<input type="checkbox"/>
32	BELGRADER, P. et al.; A Battery-Powered Notebook Thermal Cycler for Rapid Multiplex Real-Time PCR Analysis; Analytical Chemistry; 2001; pp. 286-289; Vol 73, No. 2.	<input type="checkbox"/>
33	AROCA, R. et al.; Surface-Enhanced Raman Scattering of Langmuir-Blodgett Monolayers of Phthalocyanine by Indium and Silver Island Films; J. Phys. Chem.; 1985; pp. 4051-4054; Vol. 89.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10536502
Filing Date	2005-12-14
First Named Inventor	Chris D. Geddes
Art Unit	2858
Examiner Name	
Attorney Docket Number	014835-101.02-029

34	SOKOLOV, K. et al.; Enhancement of Molecular Fluorescence near the Surface of Colloidal Metal Films; Analytical Chemistry; 1998; pp. 3898-3905; Vol. 70, No. 18.	<input type="checkbox"/>
35	SELVAN, S. T. et al.; Remarkable Influence of Silver Islands on the Enhancement of Fluorescence from Eu ³⁺ Ion-Doped Silica Gels; J. Phys. Chem. B; 1999; pp. 7064-7067; Vol. 103.	<input type="checkbox"/>
36	LAKOWICZ, J. R.; Review: Radiative Decay Engineering: Biophysical and Biomedical Applications; Analytical Biochemistry; 2001; pp. 1-24; Vol. 298.	<input type="checkbox"/>
37	LACOWICZ, J. R. et al.; Radiative Decay Engineering: 2. Effects of Silver Island Films on Fluorescence Intensity, Lifetimes, and Resonance Energy Transfer; Analytical Biochemistry; 2002; pp. 261-277; Vol. 301.	<input type="checkbox"/>
38	ZILINSKAS, R. A.; Iraq's Biological Weapons: The Past as Future?; JAMA; August 1997; pp. 418-424; Vol. 278(5).	<input type="checkbox"/>
39	TURNBULL, P. C. B.; Definitive identification of Bacillus anthracis - a review; Journal of Applied Microbiology; 1999; pp. 237-240; Vol. 87.	<input type="checkbox"/>
40	KEIM, P. et al.; Molecular Evolution and Diversity in Bacillus anthracis as Detected by Amplified Fragment Length Polymorphism Markers; Journal of Bacteriology; Feb. 1997; pp. 818-824; Vol. 179, No. 3.	<input type="checkbox"/>
41	KEIM, P. et al.; Multiple-Locus Variable-Number Tandem Repeat Analysis Reveals Genetic Relationships within Bacillus anthracis; Journal of Bacteriology; May 2000; pp. 2928-2936; Vol. 182, No. 10.	<input type="checkbox"/>
42	KUNST, F.; The complete genome sequence of the Gram-positive bacterium Bacillus subtilis; Nature; Nov. 1997; pp. 249-256; Vol. 390.	<input type="checkbox"/>
43	HELGASON, E. et al.; Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis - One Species on the Basis of Genetic Evidence; Applied and Environmental Microbiology; June 2000; pp. 2627-2630; Vol. 66, No. 6.	<input type="checkbox"/>
44	TAKAMI, H. et al.; Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and genomic sequence comparison with Bacillus subtilis; Nucleic Acids Research; 2000; pp. 4317-4331; Vol. 28, No. 21.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10536502
Filing Date		2005-12-14
First Named Inventor	Chris D. Geddes	
Art Unit	2858	
Examiner Name		
Attorney Docket Number	014835-101.02-029	

45	ARONSON, A.; Sporulation and delta-endotoxin synthesis by Bacillus thuringiensis; Cell. Mol. Life Sci.; 2002; pp. 417-425; Vol. 59.	<input type="checkbox"/>
46	OKINAKA, R. T. et al.; Sequence and Organization of pX01, the Large Bacillus anthracis Plasmid Harboring the Anthrax Toxin Genes; Journal of Bacteriology; Oct. 1999; pp. 6509-6515; Vol. 181, No. 20.	<input type="checkbox"/>
47	OKINAKA, R. et al.; Sequence, assembly and analysis of pX01 and pX02; Journal of Applied Microbiology; 1999; pp. 261-262; Vol. 87.	<input type="checkbox"/>
48	RAMISSE, V. et al.; The Ba813 chromosomal DNA sequence effectively traces the whole Bacillus anthracis community; Journal of Applied Microbiology; 1999; pp. 224-228; Vol. 87.	<input type="checkbox"/>
49	MICHAELS, A. M. et al.; Ag Nanocrystal Junctions as the Site for Surface-Enhanced Raman Scattering of Single Rhodamine 6G Molecules; J. Phys. Chem. B; 2000; pp. 11965-11971; Vol. 104.	<input type="checkbox"/>
50	FREEMAN, R. G. et al.; Self-Assembled Metal Colloid Monolayers: An Approach to SERS Substrates; Science, New Series (JSTOR); Mar. 1995; pp. 1629-1632; Vol. 267, No. 5204.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10536502
Filing Date	2005-12-14
First Named Inventor	Chris D. Geddes
Art Unit	2858
Examiner Name	
Attorney Docket Number	014835-101.02-029

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	
Name/Print		Registration Number	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.